相关实验视频

Updated: Jul 13, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

多价值,不对称的IL-2-Fc融合显示了对调节性T细胞的增强选择性

Brian T Orcutt-Jahns¹, Peter C Emmel¹, Eli M Snyder¹

¹Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.

Science signaling

|October 17, 2023

概括

为了针对自身免疫性疾病,工程介质素-2 (IL-2) 需要对调节性T (Treg) 细胞增强的特异性. 这项研究优化了IL-2变体,专注于对高亲和感受体的狂热效应,显著改善了Treg选择性.

科学领域:

免疫学免疫学免疫学
分子生物学分子生物学
生物技术是生物技术.

背景情况:

互白素-2 (IL-2) 在治疗自身免疫性疾病方面表现有前途.
目前的IL-2疗法受到免疫抑制调节T (Treg) 细胞的低特异性限制.
结合IL-2受体的亲和力和细胞特异性取决于α,β和γ链的组合.

研究的目的:

设计具有对Treg细胞特异性提高的IL-2变体.
调查贪效应在优化Treg选择性的作用.
为了确定最佳的细胞表面点,以增强Treg点.

主要方法:

在人类免疫细胞中,利用具有多种亲和力和价值力的工程IL-2-Fc融合,对人类免疫细胞的信号响应进行分析.
开发一种多价值结合和二元增强激素的模型,以解释Treg选择性.
设计和测试四价位IL-2-Fc融合和不对称的多价位设计.

主要成果:

针对高亲和度IL-2受体的以贪为中心的设计增强了Treg选择性.
一个结合多价值结合和狂热度的模型准确地预测了信号响应.
四价IL-2-Fc融合和不对称的设计在体外显示出优越的Treg选择性.
IL2Rα被确定为最大限度地提高Treg选择性的最佳目标.

结论:

优化对Treg细胞的IL-2特异性可以通过利用狂热效应来实现,特别是对IL2Rα点.
具有增强狂热度的工程IL-2变体为自身免疫性疾病提供了一个有前途的治疗策略.
这项工作为设计下一代基于IL-2的免疫疗法提供了框架.

更多相关视频

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

相关概念视频

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.